B
Bullisch
Bullisch · 25%SPRC
$7.05
Szenariopreis
$1.400
-0.247 (-17.65%)Zum Schluss
Loading chart…
- Hoch
- 1.720
- Eröffnung
- 1.630
- Volumengewichteter Durchschnittskurs
- 1.51
- Volumen
- 220.19K
- Marktkap.
- 2.77M
- Tief
- 1.400
- Umsatz
- 331.75K
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
KI-Analyse of Scisparc Ltd (SPRC)
VerkaufenGiven the current price of $1.70 and an RSI of 6.99, which indicates extreme oversold conditions, there may be potential for a short-term bounce. However, the stock has experienced a staggering 95.62% decline over the past year and a 61.97% drop in the last five days, indicating severe underlying issues. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, and the gross margin has dropped to 0% in the latest quarter, reflecting significant operational challenges. The main risk is the company's negative EPS of -299.94 for Q4 2025, indicating ongoing losses. Therefore, while there may be a potential for recovery, the current financial health and performance metrics suggest that this is not a good time to buy.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Scisparc Ltd (SPRC) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -7.61.
Alphio-AI-Kursszenarien für SPRC
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
4.510-19NewsfilterSciSparc Shifts Strategic Focus to Agentic AI Technologies
- 4.510-15Newsfilter
SciSparc Shifts Strategic Focus to Agentic AI Technologies
- 8.509-02Newsfilter
NeuroThera Pursues FDA Orphan Drug Designation for SCI-110
- 4.508-26Newsfilter
SciSparc Appoints AI Expert to Strengthen Strategic Focus
- 8.508-12Newsfilter
NeuroThera Secures Japanese Patent for Pain Treatment
SPRC FAQ – beantwortet von Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $1.70 and an RSI of 6.99, which indicates extreme oversold conditions, there may be potential for a short-term bounce. However, the stock has experienced a staggering 95.62% decline over the past year and a 61.97% drop in the last five days, indicating severe underlying issues. The forward P/E ratio is 0, suggesting no earnings growth is expected in the near future, and the gross margin has dropped to 0% in the latest quarter, reflecting significant operational challenges. The main risk is the company's negative EPS of -299.94 for Q4 2025, indicating ongoing losses. Therefore, while there may be a potential for recovery, the current financial health and performance metrics suggest that this is not a good time to buy.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.